pcsk9 regulates ldlr turnover through increased intracellular degradation
DESCRIPTION
PCSK9 Regulates LDLR Turnover Through Increased Intracellular Degradation. Genetics PCSK9. PCSK9-Directed Therapies in Development. Alirocumab (SAR236553) Change in LDL-C at 2- and 4-Week Dosing Intervals on Atorvastatin. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: PCSK9 Regulates LDLR Turnover Through Increased Intracellular Degradation](https://reader031.vdocuments.us/reader031/viewer/2022020800/56812d2c550346895d922b1c/html5/thumbnails/1.jpg)
![Page 2: PCSK9 Regulates LDLR Turnover Through Increased Intracellular Degradation](https://reader031.vdocuments.us/reader031/viewer/2022020800/56812d2c550346895d922b1c/html5/thumbnails/2.jpg)
![Page 3: PCSK9 Regulates LDLR Turnover Through Increased Intracellular Degradation](https://reader031.vdocuments.us/reader031/viewer/2022020800/56812d2c550346895d922b1c/html5/thumbnails/3.jpg)
PCSK9 Regulates LDLR Turnover Through Increased Intracellular
Degradation
![Page 4: PCSK9 Regulates LDLR Turnover Through Increased Intracellular Degradation](https://reader031.vdocuments.us/reader031/viewer/2022020800/56812d2c550346895d922b1c/html5/thumbnails/4.jpg)
Genetics PCSK9
![Page 5: PCSK9 Regulates LDLR Turnover Through Increased Intracellular Degradation](https://reader031.vdocuments.us/reader031/viewer/2022020800/56812d2c550346895d922b1c/html5/thumbnails/5.jpg)
PCSK9-Directed Therapies in Development
![Page 6: PCSK9 Regulates LDLR Turnover Through Increased Intracellular Degradation](https://reader031.vdocuments.us/reader031/viewer/2022020800/56812d2c550346895d922b1c/html5/thumbnails/6.jpg)
Alirocumab (SAR236553)Change in LDL-C at 2- and 4-Week Dosing Intervals on
Atorvastatin
![Page 7: PCSK9 Regulates LDLR Turnover Through Increased Intracellular Degradation](https://reader031.vdocuments.us/reader031/viewer/2022020800/56812d2c550346895d922b1c/html5/thumbnails/7.jpg)
Evolocumab (AMG 145) Change in LDL-C at 2- and 4-Week Dosing
Intervals on Statin Therapy
![Page 8: PCSK9 Regulates LDLR Turnover Through Increased Intracellular Degradation](https://reader031.vdocuments.us/reader031/viewer/2022020800/56812d2c550346895d922b1c/html5/thumbnails/8.jpg)
MENDELEvolocumab Monotherapy for Hypercholesterolemia
![Page 9: PCSK9 Regulates LDLR Turnover Through Increased Intracellular Degradation](https://reader031.vdocuments.us/reader031/viewer/2022020800/56812d2c550346895d922b1c/html5/thumbnails/9.jpg)
LAPLACE-TIMI 57 Evolocumab Combined With Statin for
Hypercholesterolemia
![Page 10: PCSK9 Regulates LDLR Turnover Through Increased Intracellular Degradation](https://reader031.vdocuments.us/reader031/viewer/2022020800/56812d2c550346895d922b1c/html5/thumbnails/10.jpg)
StatinsApproximate LDL-C Lowering Efficacy
![Page 11: PCSK9 Regulates LDLR Turnover Through Increased Intracellular Degradation](https://reader031.vdocuments.us/reader031/viewer/2022020800/56812d2c550346895d922b1c/html5/thumbnails/11.jpg)
ENHANCESimvastatin/Ezetimibe in FH
![Page 12: PCSK9 Regulates LDLR Turnover Through Increased Intracellular Degradation](https://reader031.vdocuments.us/reader031/viewer/2022020800/56812d2c550346895d922b1c/html5/thumbnails/12.jpg)
Effect of Alirocumab on LDL-C in Heterozygous FH
![Page 13: PCSK9 Regulates LDLR Turnover Through Increased Intracellular Degradation](https://reader031.vdocuments.us/reader031/viewer/2022020800/56812d2c550346895d922b1c/html5/thumbnails/13.jpg)
RUTHERFORDEffect of Evolocumab on LDL-C in Heterozygous
FH
![Page 14: PCSK9 Regulates LDLR Turnover Through Increased Intracellular Degradation](https://reader031.vdocuments.us/reader031/viewer/2022020800/56812d2c550346895d922b1c/html5/thumbnails/14.jpg)
GAUSSEvolocumab in Statin Intolerance
![Page 15: PCSK9 Regulates LDLR Turnover Through Increased Intracellular Degradation](https://reader031.vdocuments.us/reader031/viewer/2022020800/56812d2c550346895d922b1c/html5/thumbnails/15.jpg)
PCSK9-Directed Therapies in Development
![Page 16: PCSK9 Regulates LDLR Turnover Through Increased Intracellular Degradation](https://reader031.vdocuments.us/reader031/viewer/2022020800/56812d2c550346895d922b1c/html5/thumbnails/16.jpg)
OSLER Extension Study
![Page 17: PCSK9 Regulates LDLR Turnover Through Increased Intracellular Degradation](https://reader031.vdocuments.us/reader031/viewer/2022020800/56812d2c550346895d922b1c/html5/thumbnails/17.jpg)
OSLEREffect of Evolocumab on LDL-C after 52 Weeks
![Page 18: PCSK9 Regulates LDLR Turnover Through Increased Intracellular Degradation](https://reader031.vdocuments.us/reader031/viewer/2022020800/56812d2c550346895d922b1c/html5/thumbnails/18.jpg)
Clinical Utility of PCSK9 Inhibitors
![Page 19: PCSK9 Regulates LDLR Turnover Through Increased Intracellular Degradation](https://reader031.vdocuments.us/reader031/viewer/2022020800/56812d2c550346895d922b1c/html5/thumbnails/19.jpg)
Phase 3 Trials
![Page 20: PCSK9 Regulates LDLR Turnover Through Increased Intracellular Degradation](https://reader031.vdocuments.us/reader031/viewer/2022020800/56812d2c550346895d922b1c/html5/thumbnails/20.jpg)
Use of PCSK9 InhibitorsBased on Evidence or Definitive Outcomes Data?
![Page 21: PCSK9 Regulates LDLR Turnover Through Increased Intracellular Degradation](https://reader031.vdocuments.us/reader031/viewer/2022020800/56812d2c550346895d922b1c/html5/thumbnails/21.jpg)
Abbreviations
![Page 22: PCSK9 Regulates LDLR Turnover Through Increased Intracellular Degradation](https://reader031.vdocuments.us/reader031/viewer/2022020800/56812d2c550346895d922b1c/html5/thumbnails/22.jpg)
Abbreviations (cont)
![Page 23: PCSK9 Regulates LDLR Turnover Through Increased Intracellular Degradation](https://reader031.vdocuments.us/reader031/viewer/2022020800/56812d2c550346895d922b1c/html5/thumbnails/23.jpg)
References
![Page 24: PCSK9 Regulates LDLR Turnover Through Increased Intracellular Degradation](https://reader031.vdocuments.us/reader031/viewer/2022020800/56812d2c550346895d922b1c/html5/thumbnails/24.jpg)
References (cont)
![Page 25: PCSK9 Regulates LDLR Turnover Through Increased Intracellular Degradation](https://reader031.vdocuments.us/reader031/viewer/2022020800/56812d2c550346895d922b1c/html5/thumbnails/25.jpg)
References (cont)